[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mrd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mrd":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,43,79,102,127,152,176,204],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100601601","minimal-residual-disease-used-in-predicting-therapeutic-efficacy-in-metastatic-hormone-sensitive-prostate-cancer-100601601",false,"NCT07112612","Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer","Application of Personalized Minimal Residual Disease in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer","Inclusion Criteria:\n\n1. Aged 18 years and younger than 85 years;\n2. Patients diagnosed with prostate acinar adenocarcinoma, ductal adenocarcinoma, or intraductal carcinoma by pathological histology;\n3. Patients with clear distant metastases found by imaging (in accordance with RECIST criteria);\n4. Patients with locally advanced (N1) and metastatic (M1) prostate cancer at diagnosis.\n5. Patients who have not received endocrine therapy or other systemic anti-tumor treatments in the past;\n6. ECOG score of 0-2 points, with an expected survival period of more than 6 months;\n7. Patients with normal organ function;\n8. Routine blood test (no blood transfusion or blood products within 14 days):\n\n   Hemoglobin (HGB) ≥ 90g\u002FL; Absolute neutrophil count (ANC) ≥ 1.5×109\u002FL (1500 \u002Fmm3); Platelet count (PLT) ≥ 75×109\u002FL; White blood cell count (WBC) ≥ 3×109\u002FL;\n9. Biochemical examination:\n\n   Total bilirubin (TBIL) ≤ upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 ULN; Creatinine clearance (CCr) ≥ 30ml\u002Fmin; (Cockcroft-Gault formula);\n10. Coagulation function: prothrombin international normalized ratio (INR) ≤ 1.5 or prothrombin time (PT) \\\u003C 4 seconds;\n11. Patients agree to sign informed consent and are able to attend scheduled study visits, provide clinical information, and cooperate with other study procedures.\n\nExclusion Criteria:\n\n* (1) Patients diagnosed with neuroendocrine\u002Fsmall cell prostate cancer by pathological histology; (2) No clear distant metastasis was found by imaging (in accordance with RECIST criteria); (3) Patients with a history of previous treatment: including neoadjuvant and adjuvant therapy; (4) The samples submitted for examination failed to meet the quality control requirements.\n\n  (5) Patients with combined endocrine, metabolic system diseases or other serious digestive system diseases; (6) Patients with combined chronic hepatitis, cirrhosis, chronic nephritis, renal insufficiency and other diseases; (7) Patients with a history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; (8) Patients with a history of other malignant tumors; (9) Patients enrolled in other clinical trials; (10) Patients unable to obtain the clinical information required for the study (e.g., patients lost to follow-up); (11) Other situations that the researchers consider unsuitable for enrollment.","MALE","18 Years","85 Years",{"count":20,"type":21},50,"ESTIMATED","OBSERVATIONAL","This study is a prospective, single-center, observational study of patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). Minimal residual disease (MRD) detection is used to investigate the actual efficacy responses of mHSPC patients with different gene mutation characteristics to treatment regimens. Factors influencing efficacy are further analyzed to provide a basis for the precise clinical diagnosis and treatment of mHSPC patients.",[25,26,27],"MRD","Prostate Cancer","mHSPC",[29,25,30],"minimal residual disease","PCa","NOT_YET_RECRUITING","2026-01-08",{"date":34,"type":35},"2026-01-12","ACTUAL",{"date":37,"type":21},"2026-01-30",{"date":39,"type":21},"2027-04-30",{"name":41,"class":42},"Anhui Medical University","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100602222","phase-2-adaptive-adjuvant-sintilimab-therapy-guided-by-mrd-adapt-lung-100602222","NCT07120698","Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)","Adaptive Adjuvant Sintilimab Therapy Guided by MRD in II-IIIB Stage NSCLC Patients With Non-pCR Pathological Response After Neoadjuvant Immunotherapy Combined With Chemotherapy: a Prospective, Multi-center, Single-arm, Phase II Trial","CTONG 2508","Inclusion Criteria:\n\n1. Signed written informed consent prior to the initiation of any trial-related procedures.\n2. Male or female aged ≥18 years and ≤75 years.\n3. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).\n4. Received 3-4 cycles of neoadjuvant immunotherapy (PD-1 inhibitor) combined with chemotherapy.\n5. Underwent radical surgical treatment (R0), with surgical procedures including lobectomy or sleeve lobectomy. All gross tumors must be completely resected at the end of surgery, and all surgical margins of the resected tumors must be negative. Systemic lymph node dissection is required.\n6. Clinical stage II, IIIA, or IIIB (limited to resectable N2) according to the AJCC 8th edition TNM classification for lung cancer. Resectable N2 refers to non-massive (defined as short-axis diameter \\\u003C3 cm), discrete, or single-station N2 involvement. If clinically suspected of N2 or N3, pathological confirmation is recommended whenever feasible.\n7. Patients with pathological response assessment of 1%-90% residual viable tumor (RVT).\n8. No EGFR mutations, ROS1 fusions, ALK fusions, or RET fusions. Other potentially targetable driver gene alterations will be determined in consultation with the sponsor.\n9. No prior anti-tumor treatment other than PD-1 inhibitors and chemotherapy before radical surgery for lung cancer.\n10. Completed radical surgery for lung cancer 4-12 weeks prior to study enrollment, with pathological confirmation of R0 resection and radiological evidence of no residual tumor foci 1 month after radical surgery.\n11. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n12. Life expectancy \\>6 months.\n13. Adequate organ function:\n\n1\\. Absolute neutrophil count (ANC) ≥1.5×10\\^9\u002FL without the use of granulocyte colony-stimulating factor within the past 14 days.\n\n2\\. Platelets ≥100×10\\^9\u002FL without transfusion within the past 14 days. 3. Hemoglobin \\>9 g\u002FdL without transfusion or use of erythropoiesis-stimulating agents within the past 14 days.\n\n4\\. Total bilirubin ≤1.5× upper limit of normal (ULN). 5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN (subjects with liver metastases are allowed to have ALT or AST ≤5×ULN).\n\n6\\. Serum creatinine ≤1.5×ULN and creatinine clearance (calculated using the Cockcroft-Gault formula) ≥60 ml\u002Fmin.\n\n7\\. Good coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN.\n\n8\\. Normal thyroid function, defined as thyroid-stimulating hormone (TSH) within the normal range. Subjects with baseline TSH outside the normal range are eligible if total T3 (or free T3) and free T4 are within the normal range.\n\n9\\. Cardiac enzyme profile within the normal range (subjects with isolated laboratory abnormalities deemed not clinically significant by the investigator are also eligible).\n\n14\\. For female subjects of childbearing potential, a negative urine or serum pregnancy test must be obtained within 3 days prior to the first administration of the study drug (Day 1 of Cycle 1). If the urine pregnancy test result is inconclusive, a serum pregnancy test is required. Postmenopausal women are defined as those who have been amenorrheic for at least 1 year, or those who have undergone surgical sterilization or hysterectomy.\n\n15\\. All subjects (regardless of gender) at risk of conception must use contraception with a failure rate of less than 1% per year throughout the treatment period until 120 days after the last administration of the study drug (or 180 days after the last administration of chemotherapy).\n\n16\\. Provide samples for MRD assessment (surgical tissue + blood).\n\nExclusion Criteria:\n\n1. Diagnosis of any malignancy other than non-small cell lung cancer within 5 years prior to the first dose (excluding completely treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and\u002For carcinoma in situ that has been completely resected).\n2. Received adjuvant radiotherapy prior to dosing.\n3. Patients who underwent pneumonectomy.\n4. Currently participating in an interventional clinical study or received other investigational drugs or used investigational devices within 4 weeks prior to the first dose.\n5. Received neoadjuvant treatment with anti-tumor therapies other than chemotherapy and immunotherapy.\n6. Presence of unhealed surgical incisions, ulcers, or fractures.\n7. In the investigator's opinion, severe concomitant systemic diseases that may affect the subject's ability to complete the study. Subjects with positive autoimmune antibodies must be assessed and confirmed by the investigator to have no autoimmune diseases requiring systemic treatment before enrollment.\n8. Presence of primary immunodeficiency diseases.\n9. Receiving systemic corticosteroid therapy within 7 days prior to the first dose of the study (excluding intranasal, inhaled, or other topical corticosteroids). Note: The use of physiologic doses of corticosteroids (≤10 mg\u002Fday prednisone or equivalent) is permitted.\n10. Known allogeneic organ transplantation (excluding corneal transplantation) or allogeneic hematopoietic stem cell transplantation.\n11. Known allergy to the active ingredient or excipients of the study drug, sintilimab.\n12. Not fully recovered from toxicities and\u002For complications caused by any prior interventions prior to the start of treatment (i.e., ≤Grade 1 or returned to baseline, excluding fatigue or alopecia).","ALL","28 Years","75 Years",{"count":55,"type":21},115,"INTERVENTIONAL",[58],"PHASE2","This is a multicenter, prospective, open-label Phase II study designed to evaluate the safety and efficacy of adjuvant sintilimab therapy guided by minimal residual disease (MRD) in patients with Stage II-IIIB non-small cell lung cancer (NSCLC) who have not achieved a pathological complete response (non-pCR) after neoadjuvant immunotherapy combined with chemotherapy. The study is being conducted at the Third People's Hospital of Chengdu and the Guangdong Provincial People's Hospital.",[61,25,62,63],"NSCLC (Non-small Cell Lung Cancer)","II-IIIB Stages","Adjuvant Immunotherapy",[25,65,66,67],"II-IIIB stages","NSCLC (non-small cell lung cancer)","adjuvant immunotherapy","RECRUITING","2025-12-30",{"date":71,"type":35},"2026-01-05",{"date":73,"type":35},"2025-11-05",{"date":75,"type":21},"2029-07-26",{"name":77,"class":42},"Guangdong Association of Clinical Trials",2,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100612482","a-study-of-tumor-agnostic-mrd-detection-in-stage-iii-colorectal-cancer-100612482","NCT07254156","A Study of Tumor-Agnostic MRD Detection in Stage III Colorectal Cancer","A Prospective, Multicenter, Exploratory Clinical Study Evaluating the Application of Tissue-Agnostic Technology in the Dynamic Monitoring of Minimal Residual Disease in Stage III Colorectal Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically confirmed colorectal cancer.\n* Preoperatively assessed as stage III according to the 8th edition UICC\u002FAJCC staging system.\n* Deemed eligible for radical resection upon investigator assessment.\n* No prior anti-tumor therapy received.\n* ECOG PS score 0-1.\n* Willing and able to provide signed informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Has a history of other malignant tumors.\n* Pregnant and lactating women.\n* Presence of any concurrent medical or psychiatric condition, as assessed by the investigator, that may interfere with protocol compliance, study follow-up, or affect short-term survival.",{"count":87,"type":21},229,"This observational study aims to evaluate the predictive performance of various omics-based methods for detecting minimal residual disease (MRD) in stage III colorectal cancer. The study involves the collection of blood samples from patients who have accepted surgery for colorectal cancer. Blood samples will be analyzed using both tumor-informed and tumor-agnostic approaches to detect circulating tumor DNA (ctDNA). The study will compare the sensitivity of these methods and assess their correlation with recurrence risk. The findings aim to inform the development of optimal MRD detection strategies, ultimately providing a robust molecular basis for personalized treatment decisions.",[90,25,91],"Colorectal Cancer","ctDNA","2025-11-19",{"date":94,"type":35},"2025-11-28",{"date":96,"type":21},"2025-11-24",{"date":98,"type":21},"2028-12-31",{"name":100,"class":42},"Sun Yat-sen University",1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":56,"phases":110,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":101},"100609508","a-clinical-study-on-minimal-residual-disease-in-patients-with-systemic-light-chain-amyloidosis-100609508","NCT07215494","A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis","Inclusion Criteria:\n\n1. Age range: 18-70 years (inclusive), no gender restriction;\n2. Newly diagnosed AL amyloidosis patients;\n3. Meet ASCT eligibility criteria and have a willingness to undergo ASCT;\n4. Achieved hematological complete response (CR) after 2-4 cycles of Dara-CyBorD induction chemotherapy.\n\nExclusion Criteria:\n\n1. Secondary to multiple myeloma or lymphoplasmacytic lymphoma, such as Waldenström's macroglobulinemia;\n2. Co-existing other active malignant tumors;\n3. Co-existing other systemic diseases deemed unsuitable for inclusion by the investigator, such as newly developed severe cardiovascular and cerebrovascular diseases, or severe infections.","70 Years",{"count":20,"type":21},[111],"NA","Before effective treatment, the prognosis of patients with AL amyloidosis is very poor, with a median survival of approximately 12 months. In recent decades, with the development of new drugs, the treatment paradigm for AL amyloidosis has undergone significant changes, and the prognosis has improved dramatically. Achieving very good partial response (VGPR) or even complete response (CR) can lead to higher organ response and longer survival. However, not all patients who achieve ≥VGPR reach organ response, which may be related to the presence of small residual plasma cell clones in these patients. The ongoing production of monoclonal light chains deposits into tissues and organs, causing continuous damage, making organ response difficult. With the development of new drugs, the rate of hematologic CR has continuously increased, and the advancement of minimal residual disease (MRD) detection technologies in recent years has led to increasing attention to MRD in AL amyloidosis research. Therefore, in this era of advancing new drugs, MRD negativity may become a higher clinical treatment goal for AL amyloidosis, further improving long-term prognosis for patients.\n\nOur department plans to conduct a single-center, prospective clinical study aimed at exploring the MRD status in patients who achieve hematologic CR after first-line induction chemotherapy (Dara-CyBorD), and further investigating whether autologous stem cell transplantation in MRD-positive CR patients who meet transplant criteria can further improve organ response, progression-free survival, and overall survival.",[114,25],"Light Chain (AL) Amyloidosis",[116,25,117],"light chain amyloidosis","ASCT","2025-10-02",{"date":120,"type":35},"2025-10-10",{"date":122,"type":21},"2025-10",{"date":124,"type":21},"2029-09",{"name":126,"class":42},"Peking University First Hospital",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":56,"phases":136,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":101},"100547571","phase-4-treatment-of-high-risk-newly-diagnosed-multiple-myeloma-with-minimal-residual-disease-detection-100547571","NCT06409702","Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection","A Single-arm Prospective Study of the Treatment in High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection","Inclusion Criteria:\n\n1. patients with newly diagnosed multiple myeloma（may receive up to one course of a bortezomib-containing regimen for the urgent relief of bone pain, renal insufficiency, and hypercalcemia）;\n2. age ≥ 18 years;\n3. have an evaluable lesion; serum M protein ≥ 10 g\u002FL, or urinary light chain ≥ 200 mg\u002F24h, or involved serum free light chain (FLC) ≥ 100 mg\u002FL, and an extramedullary measurable tumor SPD: The diameter of cutaneous nodules can be measured with a manual tape, and extramedullary tumor SPD of extramedullary tumors is measured on a CT scan as the product of the largest dimension of the largest pendulous diameter of the lesion (minimum diameter of 5mm or more), parosteal lesions need to be in soft tissue outside the bone cavity to meet the above criteria. MRI measures the size of an extramedullary tumor as the product of the maximum pendulous diameter at the level of the largest area of the tumor (minimum diameter of 5mm or more)\n4. ECOG physical status score ≤ 2\n5. or have a high-risk karyotype abnormality recognized in mSMART or NCCN guidelines: t(4;14), t(14;16), t(14;20), Del(17p) or -17 and\u002For TP53 mutation, Del(1p32), 1q21 gain(amp), the coexistence of two adverse karyotypes as a double hit,and triple hit similarly defined\n6. or R-ISS stage 3\n7. or combined plasma cell leukemia (defined as peripheral blood sorted clonal plasma cells ≥ 5%)\n8. bone marrow function: neutrophils ≥ 1.0 x 109 \u002FL, platelets ≥ 70 x 109 \u002FL (if bone marrow plasma cells ≥ 50%, platelets ≥ 50 x 109 \u002FL)\n9. AST, ALT, ALP ≤ 3 × upper limit of normal value, serum bilirubin ≤ 2 times upper limit of normal value;\n10. serum creatinine clearance ≥ 40mL\u002Fmin\n11. negative pregnancy test for women of childbearing age; patients and their spouses must agree to use effective contraception during the treatment period and the following one-year period;\n12. Signed informed consent for chemotherapy. A legal representative will sign the informed consent form if the subject is unable to sign it due to impaired consciousness, paralysis of the subject's upper limbs, or inability to write.\n\nExclusion Criteria:\n\n1. monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, primary light chain amyloidosis with organ involvement.\n2. diagnosed or treated for another malignancy prior to pre-registration ≤ 1 year or previously diagnosed with another malignancy with evidence of any residual disease being treated.\n3. other co-morbidities that would interfere with the subject's ability to participate in the trial, e.g., uncontrolled infections, uncompensated cardiac or pulmonary disease, other synchronized chemotherapy or any adjuvant therapy considered investigational.\n4. peripheral neuropathy ≥ grade 1-2 with pain on clinical examination within 30 days prior to pre-registration\n5. major surgery within 14 days prior to pre-registration\n6. evidence of current uncontrolled cardiovascular disease, including uncontrolled hypertension (hypertension defined as SBP ≥ 140 mmHg and\u002For DBP ≥ 90 mmHg on 3 non-same day office measurements without antihypertensive medication), arrhythmias (prolonged QT interval, ventricular tachycardia, ventricular flutter, ventricular fibrillation, frequent ventricular premature beats (24 h ventricular premature load ≥ 15% of the total number of heart beats, atrioventricular block, heart rate \\\u003C30-40 bpm), congestive heart failure, unstable angina or myocardial infarction. New York Heart Association (NYHA) Class III, IV heart failure.\n7. Participants with known chronic obstructive pulmonary disease (COPD) (defined as exertional expiratory volume in 1 second \\[FEV1\\] \\\u003C50% of predicted normal volume), persistent asthma, or a history of asthma within the past 2 years (controlled intermittent asthma or mild persistent asthma is permitted). Participants with known or suspected COPD must have FEV1 testing during screening.\n8. moderate\u002Fsevere renal insufficiency: creatinine clearance \\\u003C 40mL\u002Fmin.\n9. known human immunodeficiency virus (HIV) positivity.\n10. Hepatitis B seropositivity (defined as a positive Hepatitis B surface antigen \\[HBsAg\\] test). Subjects whose infection has resolved (i.e., subjects who are HBsAg negative but positive for Hepatitis B Core Antigen Antibody \\[anti-HBc\\] and\u002For Hepatitis B Surface Antigen Antibody \\[anti-HBs\\]) must be screened for Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) levels using real-time Polymerase Chain Reaction (PCR). PCR-positive subjects will be excluded. Exception:Subjects with serologic results suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) and a known history of prior HBV vaccination do not need to be tested for HBV DNA by PCR.\n11. known or suspected active hepatitis C infection.\n12. any medical or psychiatric condition that, in the opinion of the investigator, may interfere with the completion of treatment under this protocol.\n13. known allergy or intolerance to the test drug.\n14. inability to comply with the protocol\u002Fprocedure.\n15. Subjects will be ineligible to participate in the trial because the genotoxic, mutagenic, and teratogenic effects of the investigational drug(s) involved in this trial on the developing fetus and neonate are unknown if any of the following conditions are present at the time of screening: Pregnant women, lactating mothers, males or females of childbearing potential who refuse adequate contraception (as per protocol).",{"count":135,"type":21},59,[137],"PHASE4","The goal of this study is to evaluate sustained MRD negativity for one year in DKRD induction \\& consolidation therapy +\u002F- ASCT in newly diagnosed high-risk multiple myeloma patients. It aims to evaluate the efficacy and safety of the combination regimen of Daratumumab in combination with carfilzomib, lenalidomide, and dexamethasone (DKRD) +\u002F- ASCT for the treatment of patients with newly diagnosed high-risk multiple myeloma. Participants will receive bortezomib based induction therapy for one cycle, and then DKRD induction for 3 cycles(+ASCT), DKRD consolidation for 2-4 cycles, and DKR maintenance treatment(adjusted according to MRD negativity after consolidation therapy)",[140,141,25,142],"Newly Diagnosed","High Risk","Multiple Myeloma","2025-06-10",{"date":145,"type":35},"2025-06-12",{"date":147,"type":35},"2024-06-12",{"date":149,"type":21},"2027-12-31",{"name":151,"class":42},"The First Affiliated Hospital of Soochow University",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":51,"minAge":4,"maxAge":4,"enrollmentInfo":159,"targetDuration":161,"studyType":22,"phases":4,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":101},"100586660","observational-clinical-study-on-role-of-mrd-in-predicting-local-therapy-in-oligometastatic-breast-cancer-100586660","NCT06918262","Observational Clinical Study on Role of MRD in Predicting Local Therapy in Oligometastatic Breast Cancer","An Observational Clinical Study to Evaluate the Role of MRD in the Prediction of Local Therapy in Patients With Oligometastatic Breast Cancer.","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed breast cancer.\n2. Previously confirmed metastatic breast cancer by imaging.\n3. Eastern Cooperative Oncology Group (ECOG) physical status score of 0-2. (4) Age ≥ 18 years at the time of signing the informed consent form. (5) Subjects willing and able to comply with the study protocol throughout the study period.\n\n(6) Female subjects of childbearing potential must agree to use a highly effective method of contraception during the study.\n\n(7) Voluntarily agree to and sign a written informed consent form and be willing and able to comply with all aspects of the trial protocol, which can be withdrawn by the patient at any time without prejudice.\n\nExclusion Criteria:\n\n1. Patients with active\u002Frefractory infections that require ongoing anti-infective therapy.\n2. Severe cardiovascular compromise (history of congestive heart failure greater than New York Heart Association (NYHA) class II), unstable angina or myocardial infarction within the past 6 months, or severe arrhythmia.\n3. Subjects with allogeneic organ transplants requiring immunosuppressive therapy. (4) Subjects known to be human immunodeficiency virus (HIV) positive.\n\n5\\) Subjects with a prior malignancy other than breast cancer, cervical cancer in situ, and non-melanoma skin cancer, unless the prior malignancy has been previously diagnosed and definitively treated for at least 5 years without evidence of subsequent recurrence.\n\n6\\) Any medical condition that, in the opinion of the Investigator, makes the subject unsuitable for entry into the study.",{"count":160,"type":21},40,"7 Months","This is an observational clinical study of MRD as a predictor of local treatment in patients with oligometastatic breast cancer. The aim of the study is to assess the correlation between MRD levels and prognosis in patients with oligometastatic breast cancer who have undergone local treatment in order to identify the population that would benefit from local treatment and to develop an individualised treatment plan. Subjects will agree to participate in this study and will be asked to collect as much medical history and demographic information as possible prior to enrolment to confirm that they meet the inclusion\u002Fexclusion criteria, and that they will undergo imaging and MRD testing prior to their first study treatment. Furthermore, subjects will undergo tumour imaging and MRD testing every 3 months (±7 days) after MRD treatment for the duration of the study, with additional investigations or more frequent tumour imaging evaluations as clinically indicated during the study.",[164,25],"Breast Cancer",[166],"Breast cancer","2025-04-05",{"date":169,"type":35},"2025-04-09",{"date":171,"type":35},"2024-01-01",{"date":173,"type":21},"2027-10-31",{"name":175,"class":42},"The First Hospital of Jilin University",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":56,"phases":186,"briefSummary":187,"conditions":188,"keywords":190,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":203},"100495882","phase-2-adaptive-treatment-for-acute-myeloid-leukemia-based-on-d14-mrd-results-100495882","NCT05736978","Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results","Clinical Efficacy and Safety of Adaptive Treatment of Acute Myeloid Leukemia (AML) Based on D14 MRD results-a Multicenter, Single-arm, Prospective Clinical Study","AVS","Inclusion Criteria:\n\n* Known and written informed consent voluntarily\n* Age ≥ 18 years\n* Newly diagnosed AML patients (per WHO 2022 classification criteria for AML diagnosis), who are not suitable for intensive chemotherapy:\n\n  * 75 years or Aged 18 to 74 years with at least one of the following comorbidities: Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or 3 or 4; Cardiac history of Congestive Heart Failure (CHF) requiring treatment or Ejection Fraction \\\u003C= 50% or chronic stable angina; Diffusing capacity of the Lung for Carbon Monoxide (DLCO) \\\u003C= 65% or Forced Expiratory Volume in 1 second (FEV1) \\\u003C= 65%; Creatinine clearance \\>= 30 mL\u002Fmin to \\\u003C 45 ml\u002Fmin; Moderate hepatic impairment with total bilirubin \\> 1.5 to \\\u003C= 3.0 × Upper Limit of Normal (ULN); Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy .\n* Liver function meets the following criteria: aspartate aminotransferase (AST) ≤ 3.0×ULN\\*; alanine aminotransferase (ALT) ≤3.0×ULN\\*; Bilirubin≤1.5×ULN\\*; For subjects \\\u003C75 years old, the bilirubin level can be ≤3.0×ULN; Unless due to leukemic organ involvement.\n* Renal function meets the following criteria: creatinine clearance ≥ 30 mL\u002Fmin (Cockroft-Gault formula)\n* Life expectancy ≥ 4 weeks\n\nExclusion Criteria:\n\n* History of any malignancies prior to study entry with exception noted in the protocol.\n* Participant has known HIV infection, active hepatitis B virus (HBV) and\u002For hepatitis C virus (HCV) .\n* Participant has known active central nervous system (CNS) involvement with AML.\n* Must not have received prior anti-AML treatment except for hydroxyurea",{"count":185,"type":21},58,[58],"This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute myeloid leukemia based on MRD results on day 14 of the first cycle.",[189,25],"AML",[191,192,193],"untreated AML","MRD results","selinexor","2023-03-13",{"date":196,"type":35},"2023-03-15",{"date":198,"type":21},"2023-03-31",{"date":200,"type":21},"2027-03-15",{"name":202,"class":42},"Shanghai Tong Ren Hospital",4,{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":211,"enrollmentInfo":212,"targetDuration":4,"studyType":56,"phases":214,"briefSummary":215,"conditions":216,"keywords":217,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":229},"100480478","phase-2-adjuvant-treatment-based-on-mrd-for-egfr-mutant-nsclc-100480478","NCT05536505","Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC","Adjuvant Treatment Based on Minimal Residual Disease for Resectable Non-squamous Non-Small-Cell-Lung-Cancer With EGFR Mutations","Inclusion Criteria:\n\n1. Written informed consent provided.\n2. Males or females aged ≥18 years, \\\u003C 80 years.\n3. Able to comply with the required protocol and follow-up procedures, and able to receive oral medications.\n4. Target population is completely resected pathological stage IB-IIIB NSCLC with EGFR exon 19 deletions, L861Q mutation, G719X mutation and exon 21 L858R activating mutation.\n5. Patients who have recovered from R0 resection including lobectomy, sleeve surgery and pneumonectomy.\n6. ECOG performance status 0-1.\n7. Life expectancy ≥12 weeks.\n8. Adequate hematological function: Absolute neutrophil count (ANC) ≥1.8 x 109\u002FL, and Platelet count ≥100 x 109\u002FL, and Hemoglobin ≥9 g\u002FdL (may be transfused to maintain or exceed this level).\n9. Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN), Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x ULN in subjects without liver metastases; ≤ 5 x ULN in subjects with liver metastases.\n10. Adequate renal function: Serum creatinine ≤ 1.25 x ULN, or ≥ 60 ml\u002Fmin.\n11. Female subjects should not be pregnant or breast-feeding.\n\nExclusion Criteria:\n\n1. Known severe hypersensitivity to icotinib, osimertinib or any of the excipients of this product.\n2. Inability to comply with protocol or study procedures.\n3. A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study.\n4. A serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease.\n5. Interstitial pneumonia.\n6. Patients with prior exposure to agents directed at the HER axis (e.g. erlotinib, gefitinib, icotinib, cetuximab, trastuzumab).\n7. Patients with prior chemotherapy or therapy with systemic anti-tumour therapy (e.g. monoclonal antibody therapy).\n8. Patients with prior radiotherapy to primary lesion or lymph nodes.\n9. History of another malignancy in the last 5 years with the exception of the following: Other malignancies cured by surgery alone and having a continuous disease-free interval of 5 years are permitted. Cured basal cell carcinoma of the skin and cured in situ carcinoma of the uterine cervix are permitted.\n10. Any unstable systemic disease (including active infection, uncontrolled hypertension (systolic pressure \\> 160mmHg, diastolic pressure \\> 100mmHg), unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).\n11. Eye inflammation or eye infection not fully treated or conditions predisposing the subject to this.\n12. Evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding giving reasonable suspicion of a disease or condition that contraindicated the use of an investigational drug or puts the subject at high risk for treatment-related complications.\n13. Patient who has active serious infection (e.g. pyrexia of or 38.0℃ over) Patients who harboring exon 20 T790M mutation, EGFR 20 insertions, ALK fusion, BRAF V600E mutation, MET amplification and KRAS mutation.","80 Years",{"count":213,"type":21},180,[58],"A prospective, multicenter clinical study designed to explore the efficacy of postoperative adjuvant EGFR-TKIs therapy based on MRD status in patients with stage IB-IIIB EGFR-mutant non-squamous non-small cell lung cancer (non-squamous NSCLC). Primary endpoints include 3-year Disease-Free Survival rate (3y-DFS) and median disease-free survival (mDFS).",[25],[218,219,220],"NSCLC","Adjuvant","EGFR mutation","2022-09-12",{"date":223,"type":35},"2022-09-14",{"date":225,"type":35},"2022-09-13",{"date":227,"type":21},"2030-10-01",{"name":77,"class":42},16]